

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 286)**

### **INSIDE INFORMATION**

#### **POSSIBLE FORMATION OF JOINT VENTURE FOR MANUFACTURING AND MARKETING HUMAN PLASMA DERIVED PRODUCTS AND POSSIBLE INVOLVEMENT IN THE CONSTRUCTION AND THE OPERATION OF PLASMAPHERESIS CENTRE**

This announcement is made by Common Splendor International Health Industry Group Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to inform the shareholders and potential investors of the Company that the Company is in discussions with independent third parties on a confidential basis regarding a possible transaction involving (i) a possible formation of joint venture in Cuba, which is expected to be engaged in the construction and development of production plant and research facility of at least 144,000 square metres with maximum yearly production capacity of 2,000 tonnes of plasma for the manufacturing and marketing of human plasma derived products; and (ii) the possible involvement in the construction and the operation of plasmapheresis centres which are expected to exclusively supply human plasma to the joint venture (collectively the “**Possible Transaction**”). As at the date of this announcement, no legally binding agreement has been entered into for the consummation of the Possible Transaction.

The Possible Transaction is subject to further negotiations and the entering into of the definitive agreement(s) between the parties and hence may or may not materialise as contemplated or at all. The Possible Transaction, if materialised, may constitute notifiable transaction(s) of the Company under Chapter 14 of the Listing Rules. The Company will make further announcement in relation thereto as and when appropriate.

**Shareholders of the Company and potential investors should note that the Possible Transaction may or may not materialise as contemplated or at all and are advised to exercise caution when dealing in the shares and other securities of the Company.**

By Order of the Board  
**Common Splendor International  
Health Industry Group Limited**  
**Cheung Wai Kuen**  
*Chairman*

Hong Kong, 16 July 2018

*As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang and Mr. Hou Kai Wen as non-executive Directors; and Mr. Mai Yang Guang, Mr. Lam Chi Wing and Mr. Wong Yiu Kit, Ernest as independent non-executive Directors.*